Dateline | Power Alley Stuff [Again!]: On May 8, 2025, it closed around $98 a share, on the NASDAQ (after an FDA complete response letter) — and that was near the 12 month low for the name. Since then, though, it has been on a pretty steady rising vector — topping $116.50, at one point in mid-July.

The news at right is largely responsible for that rise. Now we see if the sales revenue momentum machine can be re-primed, and start inching northward, as well. We will keep you posted, as we now intend to cover material events related to this finely run company.

Here’s a mostly AI-generated article on the coming Q2 results disclosures — but the guesses at number-trends look like they do accurately track the Wall Street estimates (despite being written by a dead hand):

…The pharma company is expected to post Q2 ’25 EPS of $1.96, a 2.5% decline from the year-ago quarter, while revenue is expected to come in at $6.96 billion, a marginal 0.1% increase compared to last year….

[While] Gilead reported impressive earnings last quarter, its revenue was flat with the prior year’s quarter at $6.67 billion. The company says on its website it will hold a conference call with analysts after the market closes Thursday to discuss Q2 results.

Wall Street projects flat year-over-year sales again, at $6.96 billion, and a 2% dip in EPS as the company faces a difficult comparison vs. a 50% surge in EPS in Q2 a year ago….

For its part, the outlet that ran the above pull-quote, Investors’ Business Daily, has recently upgraded its outlook on Gilead — now you know. We will likely tune in to the call tomorrow night, as we also hold a modest position in the name. Onward.

नमस्ते